 |
 |
 |
||
    |
||||
 |
||||
|
||||
HIV treatment should start earlier: experts
|
Reuters Health
Wednesday, April 8, 2009
By Ben Hirschler
LONDON (Reuters) - Patients should start taking drugs for the AIDS virus earlier to have the best chance of survival, researchers said Thursday.
An analysis of more than 45,000 people with HIV in Europe and North America found they were 28 percent more likely to develop full-blown AIDS or die if they deferred treatment until the point currently recommended in many countries.
There is no cure for the human immunodeficiency virus (HIV) that causes AIDS, but combinations of drugs can keep the virus from replicating and damaging the immune system.
Doctors normally don't start treatment until there is some evidence of damage to this system, measured by counting the number of immune cells called CD4 T-cells.
Current guidelines call for treatment only after the CD4 count falls below 350 cells per microlitre of blood.
Jonathan Sterne from Britain's University of Bristol and colleagues found waiting until the CD4 had fallen to 251-350 was associated with a significantly worse outcome than starting therapy in the range 351-450.
The team -- whose findings were published online by the Lancet journal -- concluded that a count of 350 cells should be the minimum threshold for starting treatment.
Deciding when to start taking AIDS drugs has traditionally been seen as a balancing act, since the powerful medicines can have serious side effects and there is also a risk of resistance developing.
Researchers said these problems were now easier to deal with, thanks to the advent of a wider range of drugs, and medics should therefore focus on getting patients onto therapy early.
"It is important that people at possible risk of having HIV get tested regularly so that if found to be infected they can receive the necessary care and treatment," they said.
An estimated 33 million people globally are infected with the AIDS virus, most of them living in Africa and other developing countries.
Manufacturers of AIDS drugs include GlaxoSmithKline, Pfizer , Merck, Roche and Gilead, as well as generic companies like Ranbaxy, Cipla and Aspen.
Reuters Health
© 2009 Thomson Reuters. All rights reserved. Reuters content is the intellectual property of Thomson Reuters or its third party content providers. Any copying, republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters. Thomson Reuters shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. "Reuters" and the Reuters Logo are trademarks of Thomson Reuters and its affiliated companies. For additional information on other Reuters media services please visit http://about.reuters.com/media/.
Related News:
More News on this Date
Related MedlinePlus Pages:
| Home | Health Topics | Drugs & Supplements | Encyclopedia | Dictionary | News | Directories | Other Resources | |
| Disclaimers | Copyright | Privacy | Accessibility | Quality Guidelines U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894 National Institutes of Health | Department of Health & Human Services |
Date last updated: 09 April 2009 |